Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.
Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.
复制标题
DOI：
10.1016/j.jconrel.2013.09.026
复制
发表时间：
2013-12-28
期刊：
影响因子：
--
通讯作者：
Bae YH
中科院分区：
文献类型：
--
作者：
Stirland DL;Nichols JW;Miura S;Bae YH
无数的研究论文使用临床前模型，并显示纳米颗粒设计优于目前用于治疗癌症的药物疗法，但令人惊讶的是，将这些纳米级药物载体转化为临床环境是多么的缺乏。这篇综述文章旨在比较Doxil®、PK1、Abraxane®、Genexol-PM®、Xyotax™、NC-6004、Mylotarg®、PK2和CALAA-01的临床前和临床结果。虽然不全面，但它涵盖了纳米级药物载体，旨在提高化疗中常用药物的疗效。虽然不总是可用或可比性，但努力比较动物和人类研究之间的药代动力学，毒性和功效。讨论提供了可能导致差距的原因。最后，对纳米药物载体的潜力提出了建议和鼓励。
With countless research papers using preclinical models and showing the superiority of nanoparticle design over current drug therapies used to treat cancers, it is surprising how deficient the translation of these nano-sized drug carriers into the clinical setting is. This review article seeks to compare the preclinical and clinical results for Doxil®, PK1, Abraxane®, Genexol-PM®, Xyotax™, NC-6004, Mylotarg®, PK2, and CALAA-01. While not comprehensive, it covers nano-sized drug carriers designed to improve the efficacy of common drugs used in chemotherapy. While not always available or comparable, effort was made to compare the pharmacokinetics, toxicity, and efficacy between the animal and human studies. Discussion is provided to suggest what might be causing the gap. Finally, suggestions and encouragement are dispensed for the potential that nano-sized drug carriers hold.
登录
查看更多内容
影响因子：
4.9
作者：
Alexis F;Pridgen E;Molnar LK;Farokhzad OC
通讯作者：
Farokhzad OC
影响因子：
11.5
作者：
Desai, N;Trieu, V;Soon-Shiong, P
通讯作者：
Soon-Shiong, P
影响因子：
5
作者：
Desai, Neil;Trieu, Vuong;Soon-Shiong, Patrick
通讯作者：
Soon-Shiong, Patrick
影响因子：
50.5
作者：
Brunnberg, U.;Mohr, M.;Berdel, W. E.
通讯作者：
Berdel, W. E.
影响因子：
50.5
作者：
Chan, S;Davidson, N;Lee, LW
通讯作者：
Lee, LW